ArticleCancer medicine2021

Estimating the risk of developing secondary hematologic malignancies in patients with T1/T2 prostate cancer undergoing diverse treatment modalities: A large population-based study.

Xiaofei Mo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.